Solid Biosciences (SLDB) Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Which has preferable earnings & valuation, SNDX or SLDB?

Solid Biosciences has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$43.72M	20.96	-$209.36M	-$3.86	-2.76
Solid Biosciences	$8.09M	25.87	-$96.01M	-$2.99	-0.90

Does the media favor SNDX or SLDB?

In the previous week, Solid Biosciences had 11 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 26 mentions for Solid Biosciences and 15 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.43 beat Solid Biosciences' score of 0.37 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	2 Very Positive mention(s)	8 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor SNDX or SLDB?

Syndax Pharmaceuticals received 112 more outperform votes than Solid Biosciences when rated by MarketBeat users. However, 69.65% of users gave Solid Biosciences an outperform vote while only 65.22% of users gave Syndax Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Syndax Pharmaceuticals	Outperform Votes 392 65.22%	Underperform Votes 209 34.78%
Solid Biosciences	Outperform Votes 280 69.65%	Underperform Votes 122 30.35%

Is SNDX or SLDB more profitable?

Solid Biosciences' return on equity of -58.75% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%
Solid Biosciences	N/A	-58.75%	-47.84%

Do insiders & institutionals believe in SNDX or SLDB?

81.5% of Solid Biosciences shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer SNDX or SLDB?

Syndax Pharmaceuticals presently has a consensus target price of $35.91, indicating a potential upside of 237.17%. Solid Biosciences has a consensus target price of $14.78, indicating a potential upside of 447.33%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.31

Which has more risk & volatility, SNDX or SLDB?

Syndax Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500.

Summary

Solid Biosciences beats Syndax Pharmaceuticals on 13 of the 18 factors compared between the two stocks.